Therabene
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | Mansfield, Massachusetts, U.S. |
| Headquarters | Norwood, Massachusetts, U.S. |
Key people | Mario DiPaola (CEO) Zoser Mohamed (President) Oscar Kashala (CMO) |
| Website | www |
Therabene is an American biotechnology company founded in 2020 that develops PROTAC drugs targeting proteins such as CDK9 and MYC for cancer treatment.[1][2]
History
Therabene was founded in 2020 by Mario DiPaola and initially operated from the Mansfield Bio-Incubator. The company later relocated its headquarters to Norwood, Massachusetts.[3][4][5]
In 2024, it reported preclinical results for two molecules showing tumor reduction in a triple-negative breast cancer model. In 2025, Oscar L. Kashala was appointed chief medical officer.[6][7][8]
Products
Therabene develops inhibitors and degraders targeting CDK9 and MYC for cancer treatment. Its pipeline includes TB-003, TB-008, TB-010, and TB-M002, which are in preclinical development.[9][10][11]
References
- ^ Koirala, Mahesh; DiPaola, Mario. "Targeting CDK9 in Cancer: An Integrated Approach of Combining In Silico Screening with Experimental Validation for Novel Degraders". PubMed Central. Retrieved January 16, 2026.
- ^ "Therabene Mario DiPaola PhD/MBA Protein Degraders Cancer". CEOCFO Magazine. July 17, 2023. Retrieved January 16, 2026.
- ^ "Therabene Inc. Appoints Dr. Oscar L. Kashala as Chief Medical Officer and Executive Vice President of Global Clinical Development". PharmiWeb.com. August 6, 2025. Retrieved January 16, 2026.
- ^ Hanley, Kenneth (2024-08-07). "Mario DiPaola, PhD, MBA". Top Execs. Retrieved 2026-02-13.
- ^ "Company Spotlight: Therabene". Mansfield Bio-Incubator. January 12, 2022. Retrieved January 16, 2026.
- ^ "Therabene Inc. Appoints Oscar L. Kashala as CMO and EVP of Global Clinical Development". FirstWord Pharma. August 6, 2025. Retrieved January 16, 2026.
- ^ "Therabene Appoints Dr. Oscar Kashala as CMO to Advance Protein Degrader Pipeline for Hard-to-Treat Cancers". MedPath. Retrieved January 16, 2026.
- ^ "Therabene molecules show promise in triple-negative breast cancer model". BioWorld. November 22, 2024. Retrieved January 16, 2026.
- ^ "TB-010 - Drug Targets, Indications, Patents". Patsnap Synapse. December 17, 2025. Retrieved January 16, 2026.
- ^ "Discovery of a first-in-class CDK9 degrader targeting oncogenic transcription networks in hematologic and solid tumors". Molecular Cancer Therapeutics. 24 (10 Supplement): B125. October 2025. Retrieved 2026-02-13.
- ^ "Recent Developments in Cyclin-Dependent Kinase (CDK) PROTAC in Cancer Therapy". ACS Medicinal Chemistry Letters. November 24, 2025. Retrieved January 16, 2026.